FDA Brief

Warning letters Drugs

FDA warning letter to

Taizhou Kangping Medical Science and Technology Co., Ltd.

High riskIssued Oct 9, 2025Posted Nov 11, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Taizhou Kangping about over-the-counter drugs labeled sterile that were not sterilized.

What happened

FDA inspected the Taizhou, Jiangsu, China facility from March 10 to March 14, 2025, and found violations of current good manufacturing practice (CGMP) for finished drugs, including products labeled sterile that were not sterilized and were not sterility tested. FDA also found problems with high-performance liquid chromatography (HPLC) and gas chromatography (GC) testing and data controls, including shared accounts, unretained or deleted Excel worksheets, and use of unvalidated Excel for product release. A records review also found over-the-counter product active-ingredient concentrations above the allowable range for that over-the-counter drug type.

What FDA found

  1. The firm lacked procedures to prevent microbial contamination in drug products it labeled sterile.

    21 CFR 211.113(b)
  2. Drug products labeled sterile were not sterilized, and the firm did not perform sterility testing.

    21 CFR 211.113(b)
  3. HPLC assay testing lacked proper system suitability checks and used a standard-curve frequency that could mask system drift.

    21 CFR 211.160(b)
  4. The firm did not extend its revised standard-curve testing to GC assay testing.

    21 CFR 211.160(b)
  5. GC/HPLC data controls were inadequate: Excel calculations were not retained or were deleted, accounts were shared, and unvalidated Excel was used for release.

    21 CFR 211.160(b)
  6. OTC product process controls allowed active-ingredient concentrations above the allowable range for that OTC drug type.

    section 505G of the FD&C Act

What FDA wants

FDA asks the company to respond in writing within 15 working days with corrections and prevention, including a comprehensive data-integrity investigation, a risk assessment, and a global corrective and preventive action plan (CAPA), and to notify FDA before resuming drug manufacturing.

Who should pay attention

  • U.S. pharmacies and distributors selling over-the-counter drugs from this firm
  • companies using this firm as a contract drug manufacturer
  • quality teams managing supplier qualification, sterility claims, and data integrity

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  2. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk
  3. Rohto Pharmaceutical Co., Ltd.

    FDA cites Rohto Vietnam eye-drop plant for falsified sterility records, poor aseptic practices, and unapproved Cooling Eye Drops.

    High risk
  4. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk